Literature DB >> 22068894

Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres.

Arnaud Dieudonné1, Etienne Garin, Sophie Laffont, Yan Rolland, Rachida Lebtahi, Dominique Leguludec, Isabelle Gardin.   

Abstract

UNLABELLED: Several treatment strategies are used for selective internal radiation therapy with (90)Y-microspheres. The diversity of approaches does not favor the standardization of the prescribed activity calculation. To this aim, a fast 3-dimensional (3D) dosimetry method was developed for (90)Y-microsphere treatment planning and was clinically evaluated retrospectively.
METHODS: Our 3D approach is based on voxel S values (VSVs) and has been implemented in the software tool VoxelDose. VSVs were previously calculated at a fine voxel size. The time-integrated activity (TIA) map is derived from pretherapeutic (99m)Tc-macroaggregated-albumin SPECT/CT. The fine VSV map is resampled at the voxel size of the TIA map. Then, the TIA map is convolved with the resampled VSV map to construct the 3D dose map. Data for 10 patients with 12 tumor sites treated by (90)Y-microspheres for hepatocellular carcinoma were collected retrospectively. 3D dose maps were computed for each patient, and tumoral liver and nontumoral liver (TL and NTL, respectively) were delineated, allowing the computation of descriptive statistics (i.e., mean absorbed dose, minimum absorbed dose, and maximum absorbed dose) and dose-volume histograms. Mean absorbed doses in TL and NTL from VoxelDose were compared with those calculated with the standard partition model.
RESULTS: The estimated processing time for a complete 3D dosimetry calculation is on the order of 15 min, including 10 s for the dose calculation (i.e., VSV resampling and convolution). An additional 45 min was needed for the semiautomatic and manual segmentation of TL and NTL. The mean absorbed dose (±SD) was 422 ± 263 Gy for TL and 50.1 ± 36.0 Gy for NTL. The comparison between VoxelDose and partition model shows a mean relative difference of 1.5% for TL and 4.4% for NTL. Results show a wide spread of voxel-dose values around mean absorbed dose. The minimum absorbed dose within TL ranges from 32 to 267 Gy (n = 12). The fraction of NTL volume irradiated with at least 80 Gy ranges from 4% to 70% (n = 10), and the absorbed dose from which 25% of NTL was the least irradiated ranges from 14 to 178 Gy.
CONCLUSION: This article demonstrates the feasibility of a fast 3D dosimetry method for (90)Y-microspheres and highlights the potential value of a 3D treatment planning strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22068894     DOI: 10.2967/jnumed.111.095232

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  [SPECT/CT - Technical aspects and optimization possibilities].

Authors:  W Römer
Journal:  Radiologe       Date:  2012-07       Impact factor: 0.635

2.  Assessing Spatial Concordance Between Theranostic Pairs Using Phantom and Patient-Specific Acceptance Criteria: Application to 99mTc-MAA SPECT/90Y-Microsphere PET.

Authors:  Justin K Mikell; Bill S Majdalany; Dawn Owen; Kelly C Paradis; Yuni K Dewaraja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-22       Impact factor: 7.038

3.  Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.

Authors:  Justin K Mikell; Armeen Mahvash; Wendy Siman; Veera Baladandayuthapani; Firas Mourtada; S Cheenu Kappadath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-27       Impact factor: 7.038

4.  Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.

Authors:  Arnaud Dieudonné; Robert F Hobbs; Rachida Lebtahi; Fabien Maurel; Sébastien Baechler; Richard L Wahl; Ariane Boubaker; Dominique Le Guludec; Georges Sgouros; Isabelle Gardin
Journal:  J Nucl Med       Date:  2012-12-18       Impact factor: 10.057

5.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

Review 6.  Dosimetry for radiopharmaceutical therapy.

Authors:  George Sgouros; Robert F Hobbs
Journal:  Semin Nucl Med       Date:  2014-05       Impact factor: 4.446

7.  International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.

Authors:  Hugo Levillain; Oreste Bagni; Christophe M Deroose; Arnaud Dieudonné; Silvano Gnesin; Oliver S Grosser; S Cheenu Kappadath; Andrew Kennedy; Nima Kokabi; David M Liu; David C Madoff; Armeen Mahvash; Antonio Martinez de la Cuesta; David C E Ng; Philipp M Paprottka; Cinzia Pettinato; Macarena Rodríguez-Fraile; Riad Salem; Bruno Sangro; Lidia Strigari; Daniel Y Sze; Berlinda J de Wit van der Veen; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-12       Impact factor: 9.236

8.  Yttrium-90 quantitative phantom study using digital photon counting PET.

Authors:  Joey Labour; Philippe Boissard; David Sarrut; Jean-Noël Badel; Thomas Baudier; Fouzi Khayi; David Kryza; Pascale Veyrat Durebex; Sandrine Parisse-Di Martino; Thomas Mognetti
Journal:  EJNMMI Phys       Date:  2021-07-27

9.  Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Authors:  E Garin; L Lenoir; J Edeline; S Laffont; H Mesbah; P Porée; L Sulpice; K Boudjema; M Mesbah; A Guillygomarc'h; E Quehen; M Pracht; J L Raoul; B Clement; Y Rolland; E Boucher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236

10.  Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.

Authors:  Hugo Levillain; Ivan Duran Derijckere; Lieveke Ameye; Thomas Guiot; Arthur Braat; Carsten Meyer; Bruno Vanderlinden; Nick Reynaert; Alain Hendlisz; Marnix Lam; Christophe M Deroose; Hojjat Ahmadzadehfar; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.